Longevity research is crossed with crypt through Aubrai, a decentralized science (Desci) and the AI agent launched this week at the base as part of the Bio protocol.
Decentralized science, or desci, uses blockchain and DAO to finance experiments directly, attribute credit transparently and convert the results of research into tokenized assets that allow laboratories to remain beyond philanthropy and traditional capital markets.
The Token of Aubrai, which will be launched in the launch of Bio protocol, makes the holders of the permanent interested parties in the results of the agent’s investigation, with government rights on financing decisions and a participation in the income of the discoveries marketed
Built by Vitadao and Bio protocol with the Lev of Aubrey Foundation of Gray, Aubrai aims to unite the “Death Valley”, where long -term horizon discoveries are stopped while the withdrawal of capital markets and laboratories depend on philanthropy.
De Gray is a better known biomedical gerontologist for pioneering longevity research through his strategies for insignificant engineering senescence. (Sens) frame and to advocate that aging can be treated as a curable condition.
“The consequences of traditional financing are a chronic financing gap, an excessive dependence on philanthropy and a ‘valley of death’ between discovery and clinic,” Gray told Coindesk in an interview.
“That is why we defend alternative mechanisms: DAO, risk funds centered on longevity and desci platforms, which can tolerate long horizons, align incentives around the social benefit and the risk of code code,” said De Gray.
Aubrai’s approach combines De DE Gray’s unpublished laboratory data with chain incentives. By resorting to the unpublished laboratory data of De Gray, Aubrai obtains access to exclusive ideas beyond public literature, giving the agent an advantage of first movement in the generation of novel and commercially relevant hypothesis in the science of longevity.
The agent ingests experiments in a knowledge graph, generates hypotheses and the router to the token-to-to-financing votes for financing.
“We are already seeing the agent formulate new intriguing hypotheses and recommend the next steps,” said De Gray. “It is the combination of intelligence of the expert agent and intelligence that has the potential to dramatically accelerate the advances in the fight against aging.”
Once the experiments are validated, the discoveries are accommodated in IP tokens that can graduate to pharmaceutical or biotechnological companies, with income that returns to researchers and collaborators.
The system is already in use in Robust Mouse Rejuvenation De De Gray (RMR2) studyOne of the largest lifelong life experiments that have been attempted. Aubrai has suggested methodological adjustments and dosing warnings marked that researchers had only discovered after weeks of manual review.
“Having the agent at our disposal has been a transformative for our planning pipe,” said De Gray, noting that RMR2 implies almost a dozen overlapping studies. “He identified points of consideration that we had not yet found through literature, and was proactive by suggesting ways to avoid the planned limitations.”
For Paul Kohlhaas, founder of Bio protocol, Aubrai represents a turning point in how science can be organized and financed.
“Just when Sustack gave writers the ability to monetize outside Legacy Media, Bio infrastructure can turn scientists into the next great creative economy,” he said.
Desci will face challenges
While projects such as Aubrai and Bio protocol demonstrate the potential of cryptographic capital beyond memecoras, tokenized intellectual property is likely to attract regulatory scrutiny, and established pharmaceutical companies can doubt in adopting discoveries born from decentralized groups.
However, for a field like longevity, where advances often die in space between the first results and human essays due to a selfless capital market, Aubrai offers an alternative path.
If you succeed, you could demonstrate Blockchain’s potential to do more than pump the next memecoin. It could provide infrastructure to accelerate research itself, pushing the field of longevity closer to therapies that extend human health capacity.
It would also point out that decentralized science can function as a viable market alternative to entrenched financing structures that have a restricted biomedical innovation for a long time.
